司美格鲁肽联合达格列净治疗肥胖型2型糖尿病的效果研究  

Study on the Effect of Smeglutide Combined with Dapagliflozin in the Treatment of Obese Type 2 Diabetes Mellitus

作　　者：张帅 魏静 张霞 ZHANG Shuai;WEI Jing;ZHANG Xia(Department of Nephrology and Endocrinology,Shanghe County People's Hospital,Jinan 251600,Shandong,China)

机构地区：[1]商河县人民医院肾病内分泌科,山东济南251600

出　　处：《糖尿病新世界》2025年第5期114-116,124,共4页Diabetes New World

摘　　要：目的分析司美格鲁肽联合达格列净治疗肥胖型2型糖尿病(type 2 diabetes mellitus,T2DM)的效果。方法根据不同的治疗方法,将2023年9月—2024年8月商河县人民医院收治的198例肥胖型T2DM患者分为对照组(99例,接受司美格鲁肽治疗),观察组(99例,在对照组的基础上进行达格列净治疗)。比较两组不良反应发生率、血糖、体格、胰岛功能指标。结果两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,观察组腰围、体重指数、胰岛素抵抗指数、胰岛β细胞功能指数、空腹血糖、餐后2 h血糖、糖化血红蛋白水平均优于对照组,差异均有统计学意义(P均<0.05)。结论肥胖型T2DM患者采用司美格鲁肽与达格列净联合治疗不仅可以有效控制血糖与肥胖,且改善了胰岛功能,安全性较佳。Objective To analyze the effect of smeglutide combined with dapagliflozin in the treatment of obese type 2 diabetes mellitus(T2DM).Methods According to different treatment methods,198 patients with obese T2DM admitted to Shanghe County People's Hospital from September 2023 to August 2024 were divided into control group(99 cases,treated with smeglutide),and the observation group(99 cases,treated with dapagliflozin on the basis of the control group).The incidence of adverse reactions,blood glucose,physical,islet function indexes were compared between the two groups.Results There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the waist circumference,body mass index,insulin resistance index and isletβcell function index,fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c levels in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion The combination of smeglutide and dapagliflozin in obese T2DM patients can not only effectively control blood glucose and obesity,but also improve islet function with better safety.

关 键 词：司美格鲁肽 达格列净 肥胖 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]